Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Levin

Showing results (181-190 of 217) with videos related to

Pageof 22
Sort By:
Blood|September 21, 2016
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myelomaInger S Nijhof, Laurens E Franssen, Mark-David Levin, et al.
Blood Advances|April 18, 2025
Long term follow-up of MRD guided treatment of Ibrutinib plus Venetoclax for Relapsed CLL: phase 2 VISION/HO141 trialCarsten Utoft Niemann, Julie Dubois, Kazem Nasserinejad, et al.
Experimental Hematology|August 12, 2020
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 studyFatemeh Saberi Hosnijeh, Lina van der Straten, Arnon P Kater, et al.
The Lancet. Haematology|January 2, 2026
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trialCharlotte L B M Korst, Wouter Plattel, Elizabeth A de Kort, et al.
Haematologica|September 14, 2019
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 studyLene Kongsgaard Nielsen, Claudia Stege, Birgit Lissenberg-Witte, et al.
Haematologica|December 1, 2020
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trialSonja Zweegman, Claudia A M Stege, Einar Haukas, et al.
Hemasphere|May 8, 2023
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple MyelomaChristie P M Verkleij, Kristine A Frerichs, Marloes E C Broekmans, et al.
The Lancet. Haematology|December 3, 2025
Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trialArnon P Kater, Sabina Kersting, Julie M Dubois, et al.
Journal of Hematology & Oncology|August 22, 2020
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic riskKatja Weisel, Andrew Spencer, Suzanne Lentzsch, et al.
Blood|November 22, 2024
Beyond static measurements: dynamic frailty improves survival prediction in multiple myelomaFebe Smits, Kaz Groen, Mark-David Levin, et al.
Pageof 22

Showing results (181-190 of 217) with videos related to

Sort By:
Pageof 22
Blood|September 21, 2016
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myelomaInger S Nijhof, Laurens E Franssen, Mark-David Levin, et al.
Blood Advances|April 18, 2025
Long term follow-up of MRD guided treatment of Ibrutinib plus Venetoclax for Relapsed CLL: phase 2 VISION/HO141 trialCarsten Utoft Niemann, Julie Dubois, Kazem Nasserinejad, et al.
Experimental Hematology|August 12, 2020
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 studyFatemeh Saberi Hosnijeh, Lina van der Straten, Arnon P Kater, et al.
The Lancet. Haematology|January 2, 2026
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trialCharlotte L B M Korst, Wouter Plattel, Elizabeth A de Kort, et al.
Haematologica|September 14, 2019
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 studyLene Kongsgaard Nielsen, Claudia Stege, Birgit Lissenberg-Witte, et al.
Haematologica|December 1, 2020
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trialSonja Zweegman, Claudia A M Stege, Einar Haukas, et al.
Hemasphere|May 8, 2023
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple MyelomaChristie P M Verkleij, Kristine A Frerichs, Marloes E C Broekmans, et al.
The Lancet. Haematology|December 3, 2025
Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trialArnon P Kater, Sabina Kersting, Julie M Dubois, et al.
Journal of Hematology & Oncology|August 22, 2020
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic riskKatja Weisel, Andrew Spencer, Suzanne Lentzsch, et al.
Blood|November 22, 2024
Beyond static measurements: dynamic frailty improves survival prediction in multiple myelomaFebe Smits, Kaz Groen, Mark-David Levin, et al.
Pageof 22